Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 226 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lynparza Clear all
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784
View directory record Official record
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
368
States / cities
Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Recruiting Phase 2 Interventional

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

NCT06245889
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Olaparib, Capecitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
PLX2853 20 mg, Olaparib, Abiraterone acetate, Prednisone, PLX2853 40 mg, PLX2853 80 mg
Drug
Lead sponsor
Opna Bio LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Chicago, Illinois • Detroit, Michigan • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB, Single agent chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 14, 2026, 11:45 PM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

NCT06560632
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
RP-3467 at assigned dose and schedule, Olaparib 200-300 mg BID, daily
Drug
Lead sponsor
Repare Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
San Francisco, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

NCT03976323
View directory record Official record
Conditions
Carcinoma, Nonsquamous Non-small-cell Lung
Interventions
Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Burbank, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

NCT02588105
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Results available

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

NCT01296763
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Irinotecan, Cisplatin, Olaparib (for levels 1 and 5), Olaparib (for dose level 2), Mitomycin-C
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176
View directory record Official record
Conditions
Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
AZD5153, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 14, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

NCT04666740
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate CCS1477 in Advanced Tumours

NCT03568656
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
Interventions
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

NCT05203445
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Olaparib and Durvalumab in Prostate Cancer

NCT03810105
View directory record Official record
Conditions
Prostate Cancer
Interventions
Olaparib, Durvalumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

NCT04123366
View directory record Official record
Conditions
Solid Tumors
Interventions
Olaparib, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

NCT04748042
View directory record Official record
Conditions
Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
Interventions
Abiraterone, Prednisone, External Beam Radiotherapy, Androgen Deprivation Therapy (ADT), Olaparib
Drug · Radiation · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Results available

A Study of Serum Folate Levels in Patients Treated With Olaparib

NCT04024254
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Folic Acid Deficiency
Interventions
Folic Acid Tablet
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

NCT04042831
View directory record Official record
Conditions
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Recruiting Phase 3 Interventional

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
65
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 11:45 PM EDT
Completed Phase 1 Interventional

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

NCT00678132
View directory record Official record
Conditions
Neoplasms
Interventions
AZD 2281, Cisplatin, Gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 14, 2026, 11:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
RP-3500, Olaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 14, 2026, 11:45 PM EDT
Withdrawn Phase 2 Interventional

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

NCT01661868
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 14, 2026, 11:45 PM EDT
Recruiting Phase 1 Interventional

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

NCT07382544
View directory record Official record
Conditions
Advanced Cancer, Solid Tumor
Interventions
MRTX1719, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 11:45 PM EDT